Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer
Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer
复制标题
DOI：
10.1158/1055-9965.epi-04-0722
复制
发表时间：
2005-08-01
影响因子：
3.8
通讯作者：
Hankinson, SE
中科院分区：
文献类型：
--
作者：
Bertone-Johnson, ER;Chen, WY;Hankinson, SE
一些证据表明，维生素D可以降低乳腺癌的发病率，但很少有流行病学研究讨论血浆维生素D代谢产物与乳腺癌风险的关系。在护士健康研究队列中嵌套的病例对照研究中，我们前瞻性地研究了血浆25-羟基维生素D[25(OH)D]和1，25-二羟基维生素D[1，25(OH)(2)D]水平与乳腺癌风险的关系。血液样本是在1989-1990年间从研究参与者身上采集的。在采血至1996年6月1日期间发生的乳腺癌病例，在年龄、绝经状况和其他因素的基础上与非癌症对照组相匹配。保存的701例患者和724例对照的血浆样本可用于代谢物分析。病例组平均25(OH)D水平低于对照组(P=0.01)，而1，25(OH)(2)D水平相近(P=0.49)。这两种代谢物的高水平与乳腺癌的风险降低并不显著相关。与25(OH)D含量最低的五分之一的女性相比，25(OH)D含量最高的五分之一的女性的相对危险度为0.73(95%可信区间=0.49-1.07；P趋势=0.06)。对于1，25(OH)2D，可比相对危险度为0.76(95%可信区间=0.52-1.11；P-趋势=0.39)。对于这两种代谢物，这种相关性在60岁及以上的女性中更强，但结果并不具有统计学意义。我们的发现表明，高水平的25(OH)D，也许还有1，25(OH)(2)D，可能与乳腺癌风险的降低略有关联。
Several lines of evidence suggest that vitamin D may reduce incidence of breast cancer, but few epidemiologic studies have addressed the relation of plasma vitamin D metabolites to the risk of this disease. We prospectively examined the relationship between plasma levels of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] and risk of breast cancer in a case-control study nested within the Nurses' Health Study cohort. Blood samples were collected from study participants in 1989-1990. Breast cancer cases developing between blood collection and June 1, 1996, were matched to cancer-free controls on the basis of age, menopausal status, and other factors. Stored plasma samples from 701 cases and 724 controls were available for metabolite analysis. Cases had a lower mean 25(OH)D level than controls (P = 0.01), but mean 1,25(OH)(2)D levels were similar (P = 0.49). High levels of both metabolites were associated with a nonsignificant lower risk of breast cancer. Women in the highest quintile of 25(OH)D had a relative risk of 0.73 (95% confidence interval = 0.49-1.07; P-trend = 0.06) compared with those in the lowest quintile. For 1,25(OH)2D, the comparable relative risk was 0.76 (95% confidence interval = 0.52-1.11; P-trend = 0.39). For both metabolites, the association was stronger in women ages 60 years and older, but results were not statistically significant. Our findings suggest that high levels of 25(OH)D, and perhaps 1,25(OH)(2)D, may be modestly associated with reduced risk of breast cancer.